Average Qmax improvement at 12 months = 11.2 mL/min

Immediate Flow Improvement

Months from Procedure

9.4

19.620.8 20.3

19.4

8.7

16.0

19.4 18.6

21.1

0

5

10

15

20

25

0 3 6 9 12Months from Procedure

WATER3

WATER II4

p=NS

Qm

ax (m

L/m

in)

Average IPSS improvement at 12 months = 16

Effective Sympton Relief

Months from Procedure

10.4 6.8 5.97.811.5

6.7 6.0 6.20

5

10

15

20

25

0 3 6 9 12

IPSS

Cha

nge

Months from Procedure

WATER3

WATER II4

Average resection time of 5.8 minutes

Size-independent Resection

Prostate Size (mL)

WATER1 + WATER II2

TURP

0

10

20

30

40

50

70

60

5030 70 90 110 130 150

Prostate Size (mL)

Rese

ctio

n Ti

me

(min

)

Low Surgical Complications

107.4

54.1 51.8 48.635%

23%

36%

0

20

40

60

80

100

120

Aquablation 2

(80–150mL)Aquablation 1

(30–80mL)TURP 1 PVP 5

Average Prostate Size (mL)CD2 and Above Rate (%)

20%

Reduced Irreversible Outcomes

12 Month Complication Rates (Pooled Studies: WATER3 & WATER II4)

Aquablation(30–150mL)

Incontinence 0.9%

Erectile Dysfunction 0.0%

Ejaculatory Dysfunction 14.0%

Note: CD grade definitions: CD1P (ejaculatory dysfunction, incontinence), CD2 (requiring pharmacological treatment, blood transfusions), CD3 (endoscopic or surgical interventions), CD4 (complications requiring ICU management). CD2 and Above rate calculated by summing CD2+CD3a+CD3b

Real-time multi-dimensional imaging enables complete visibility of the entire prostate

Clarity

Robotic execution delivers predictable clinical excellence across prostates of all sizes

Consistency

Precise waterjet resection reduces risk of heat-based complications

Control

Spare critical anatomies, like the bladder neck, verumontanum & external sphincter

Anatomical Preservation

Improved ability to optimize resection

Intraoperative Surgical Planning

BPH Surgery Reimagined

© 2020 PROCEPT BioRobotics Corporation. All rights reserved. AQUABLATION, AQUABEAM and PROCEPT BIOROBOTICS are the registered trademarks of PROCEPT BioRobotics Corporation.

The Apogee 2300 and ECBP-1 Bi-Plane Probe are manufactured by Shantou Institute of Ultrasonic Instruments Co. Ltd. and distributed by PROCEPT BioRobotics Corporation. SIUI is a registered trademark of Shantou Institute of Ultrasonic Instruments Co. Ltd. in the United States and other countries, and used by PROCEPT BioRobotics Corporation with permission.

ML0149.B

PROCEPT BioRobotics 900 Island Drive, Ste 210 Redwood Shores, CA 94065 United States www.PROCEPT-BioRobotics.com

Customer Service Toll Free: +1 (844) 220 5302 Direct: +1 (650) 232 7222 Fax: +1 (888) 285 3777

RISK AND SAFETY INFORMATIONAll surgical treatments have inherent and associated side effects. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

References:

1. WATER Study (6-Month Results): Gilling P, et al. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. J Urol. 2018 May; Volume 199

2. WATER II Study (6-Month Results): Desai M, et al. Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 6-Month Results from the WATER II Trial. BJUI. August 2019; Volume 124

3. WATER Study (1-Year Results): Gilling P, et al. Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-Year Outcomes. Urology. 2019 March; Volume 125

4. WATER II Study (1-Year Results): Bhojani N. et al. Aquablation for BPH in Large Prostates (80-150 mL): 1-Year Results. Urology. 2019 May; Volume 129

5. GOLIATH Study: Bachmann A, et al. 180-W XPS GreenLight Laser Vaporisation Versus TURP for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trial —The GOLIATH Study. Eur Urol. 2014 May; Volume 65